Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE)

Nowak, Agnieszka; Przywara-Chowaniec, Brygida; Damasiewicz-Bodzek, Aleksandra; Blachut, Dominika; Nowalany-Kozielska, Ewa; Tyrpień-Golder, Krystyna

doi:10.3390/cells10123523

Cited by 18 publications

(22 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may partially explain the observed lack of correlations between the PASI values and the concentrations of CML and CEL. It seems that CML and CEL are good markers of glycation in psoriasis, contrary to e.g., systemic lupus erythematosus [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients

Damasiewicz-Bodzek

Nowak

2022

Biomolecules

Self Cite

View full text Add to dashboard Cite

Psoriasis is a chronic, recurrent, and often severe skin disease which is frequently associated with metabolic disorders and increased risk of cardiovascular complications. One of the postulated links is an intensified process of advanced protein glycation and/or glycoxidation. Therefore, the aim of the study was to assess concentrations of N6-carboxymethyllysine (CML), N6-carboxyethyllysine (CEL), and soluble form of receptor for advanced glycation end-products (sRAGE) in psoriasis patients at different phases of the disease activity, in comparison to healthy individuals. The study material consisted of sera from psoriasis patients in active phase, in the remission phase, and healthy controls. Concentrations of CML, CEL, and sRAGE were determined using ELISA technique. In the patients with psoriasis (in both phases of the disease), concentrations of CML, CEL and sRAGE were significantly higher than in healthy individuals but they did not correlate with psoriasis area severity index (PASI) values. The remission of the disease was followed by a significant decrease in CML, CEL, and sRAGE concentrations when compared to active patients; however, these concentrations were still significantly higher than in the controls. Our data suggest that psoriasis is accompanied by an intense glycoxidation process and that high sRAGE levels seem to reflect permanent RAGE overstimulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients

Damasiewicz-Bodzek

Nowak

2022

Biomolecules

Self Cite

View full text Add to dashboard Cite

show abstract

“…A recent study showed excessive production of ROS, along with many other factors may induce SLE [ 22 ]. Increase in cell death and delay in clearance of these dead cells, as well as apoptotic cells are commonly associated with SLE induced excessive production of ROS [ 23 , 24 ].There are evidences of link between oxidative stress, generation of AGEs and SLE [ 25 - 27 ]. Complex and unwarranted reactions may cause the formation of AGEs, which are identified by the immune system as neoepitopes [ 28 , 29 ].…”

Section: Discussionmentioning

confidence: 99%

Glycation end-products specific auto-antibodies in Systemic Lupus Erythematosus

Khan¹

2022

Bioinformation

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease, which is highly inflammatory. Compared to a healthy control group, SLE patients exhibit a higher concentration of advanced glycation end products (AGEs) and a lower concentration of receptors for AGEs (RAGE) in serum, however, the exact aetiology is still unclear. In the present study, non-enzymatic glycation induced modification of human serum albumin (HSA) has been studied by biophysical techniques. Glycated HSA (G-HSA) was used as an antigen, and serum autoantibody levels were estimated in SLE and normal humans (NH) against it, using direct binding ELISA and competitive inhibition ELISA. Compared to N-HSA, remarkable structural modifications were observed in G-HSA. Modified HSA also showed increased pentosidine fluorescence (213.7 ± 13.4 AU). Glycation of HSA induced a conversion of α-helix and random coil to β-sheet and β-turns. Serum immuno assays results exhibited significantly (p < 0.001) higher binding of G-HSA with serum autoantibodies from SLE patients when compared with native HSA (N-HSA). Furthermore, competitive ELISA results showed significantly (p < 0.001) high percent inhibition of serum IgG from SLE patients with modified antigen. Chronic inflammation with excessive oxidative stress in SLE patients could be a possible reason for structural alterations in blood proteins, generating highly immunogenic unique new-epitopes. These in turn induce the generation of specific autoantibodies against G-HSA that may serve as a potential biomarker for SLE pathogenesis.

show abstract

“…The content of AGEs in the skin of haemodialysis patients is significantly higher than that of healthy individuals ( 33 , 41 ). Patients with severe psoriasis ( 42 ), diabetes and insulin resistance (IR) syndrome ( 43 , 44 ), and systemic lupus erythematosus ( 45 , 46 ) exhibit exacerbated production of endogenous AGEs, and the levels of AGEs in their skin were higher than those in the control group due to their persistent chronic inflammation, hyperglycaemia, or oxidative stress. In clinically, due to the differences in AGEs expression among these diseases that the skin fluorescence AGEs can utilised to predict the occurrence of diseases such as diabetes, renal or cardiovascular diseases ( 47 ).…”

Section: Brief Biochemistry Of Advanced Glycation End Productsmentioning

confidence: 99%

Advanced Glycation End Products in the Skin: Molecular Mechanisms, Methods of Measurement, and Inhibitory Pathways

Chen

Zhang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Advanced glycation end products (AGEs) are a series of stable compounds produced under non-enzymatic conditions by the amino groups of biomacromolecules and the free carbonyl groups of glucose or other reducing sugars commonly produced by thermally processed foods. AGEs can cause various diseases, such as diabetes, atherosclerosis, neurodegeneration, and chronic kidney disease, by triggering the receptors of AGE (RAGEs) in the human body. There is evidence that AGEs can also affect the different structures and physiological functions of the skin. However, the mechanism is complicated and cumbersome and causes various harms to the skin. This article aims to identify and summarise the formation and characteristics of AGEs, focussing on the molecular mechanisms by which AGEs affect the composition and structure of normal skin substances at different skin layers and induce skin issues. We also discuss prevention and inhibition pathways, provide a systematic and comprehensive method for measuring the content of AGEs in human skin, and summarise and analyse their advantages and disadvantages. This work can help researchers acquire a deeper understanding of the relationship between AGEs and the skin and provides a basis for the development of effective ingredients that inhibit glycation.

show abstract

Advanced Glycation End-Products (AGEs) and Their Soluble Receptor (sRAGE) in Women Suffering from Systemic Lupus Erythematosus (SLE)

Cited by 18 publications

References 58 publications

Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients

Concentrations of N6-Carboxymethyllysine (CML), N6-Carboxyethyllysine (CEL), and Soluble Receptor for Advanced Glycation End-Products (sRAGE) Are Increased in Psoriatic Patients

Glycation end-products specific auto-antibodies in Systemic Lupus Erythematosus

Advanced Glycation End Products in the Skin: Molecular Mechanisms, Methods of Measurement, and Inhibitory Pathways

Contact Info

Product

Resources

About